Iambic
San Diego, US · 177 employees on LinkedIn · 11 known investors
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors. It serves the pharmaceutical industry through both its own drug pipeline and partnerships.
Also known as Iambic Therapeutics
Founders & leadership
.jpg)
Investors · 11
Company profile
researched Aug 2026Iambic Therapeutics is a drug discovery company that combines proprietary artificial intelligence models with automated, high-throughput laboratory experimentation to design and advance small-molecule medicines. Its platform pairs two named AI technologies, Enchant (a multimodal transformer model) and NeuralPLexer (a co-folding model), with an experimental workflow that converts newly designed molecules into biological data on a weekly cadence. The company describes its approach as exploring multiple target product profiles in parallel so that candidate molecules are optimized against the relevant disease biology, and as searching chemical space to surface novel mechanisms of action and diverse lead series.
The company applies the platform to both known targets it considers underexploited and targets regarded as difficult to drug. Its disclosed oncology pipeline includes IAM1363, a selective, brain-penetrant HER2 inhibitor reported to have shown anti-tumor activity and tolerability in Phase 1/1b studies; IAM217, a brain-penetrant KIF18A inhibitor directed at ovarian cancer, triple-negative breast cancer and other solid tumors; and IAM-C1, a selective CDK2/4 inhibitor for HR+/HER2- metastatic breast cancer. Iambic positions its organization as a combination of AI researchers and experienced medicinal chemistry and drug development staff.
Business model
Iambic advances its own proprietary pipeline of clinical-stage small-molecule candidates while also entering collaborations with pharmaceutical companies, such as an announced arrangement with Bayer to apply its AI capabilities to drug discovery.
Traction
The company reports a HER2 program, IAM1363, with anti-tumor activity and tolerability observed in Phase 1/1b studies, two additional disclosed programs (IAM217 targeting KIF18A and IAM-C1 targeting CDK2/4), a collaboration with Bayer announced in June 2026, recognition on the CNBC Disruptor 50 list for a second consecutive year in May 2026, and participation in investor and scientific conferences including the JPMorgan Healthcare Conference in January 2026.
Latest developments
In June 2026, Iambic and Bayer announced a collaboration to advance AI-based drug discovery. In May 2026, the company was named to the CNBC Disruptor 50 list for a second consecutive year and announced participation in upcoming investor conferences. It presented a company overview at the JPMorgan Healthcare Conference in January 2026 and gave talks on AI in drug development and on its Enchant model in late 2025.
▸Full profile — market position, technology, go-to-market, geography
Market position
Iambic operates in AI-driven small-molecule drug discovery, presenting both an internal clinical oncology pipeline and pharmaceutical partnerships; it was named to the CNBC Disruptor 50 list in two consecutive years.
Iambic emphasizes purpose-built AI for drug discovery — multimodal transformer and co-folding models — integrated with automated high-throughput experimentation and operated alongside experienced drug discovery scientists, which it credits for delivering clinical candidates faster than standard industry timelines.
Technology
The platform centers on two in-house AI systems: Enchant, a multimodal transformer model aimed at linking preclinical and clinical data, and NeuralPLexer, a co-folding model. These are coupled to AI-driven, high-throughput automated experimentation that generates new biological data from newly designed molecules each week, which the company says compresses discovery timelines relative to industry norms.
Go-to-market
Oncology patient populations addressed through its own clinical programs, and pharmaceutical companies seeking AI-enabled drug discovery collaborations.
Geography
Headquartered in San Diego, California, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with Iambic for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsIambic announced a collaboration with Bayer to advance drug discovery using AI.
Iambic was included on the CNBC Disruptor 50 list for the second year in a row.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026▸Research sources · 1
primary sources listed
- Iambiciambic.ai · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Iambic do?
- Iambic Therapeutics applies AI models and automated experimentation to design small-molecule cancer drugs.
- Who founded Iambic?
- Iambic was founded by Tom Miller, Fred Manby, Thomas Miller.
- Who are Iambic's investors?
- Iambic's investors include Abingworth, Ascenta Capital, Catalio Capital Management, Alumni Ventures, Catalio Capital Management, LP, Coatue Management, Eisai Innovation, Inc., FREEFLOW and 3 more.
- Where is Iambic headquartered?
- Iambic is headquartered in San Diego, US.